EUCTR2014-000178-20-CZ进行中（未招募）1 期
Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients
Erasmus Medical Centre0 个研究点目标入组 40 人开始时间: 2015年6月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •clinical relevant mutation in the MCT8 gene leading to the clinical phenotype of AHDS
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Major illness or recent major surgery (within 4 weeks) unrelated to AHDS
- •- Patients who are participating in ongoing RCTs of therapeutic interventions (including clinical trials of investigational medicinal products);
- •- Patients that have any major contra-indication for Triac treatment (severe cardiac decompensation (NYHA 4), coronary insufficiency, severe cardiac arrhytmias, Galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption)
研究者
相似试验
进行中（未招募）
1 期
Therapy of MCT8 patients with the thyroid hormone analog Triac.This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.EUCTR2014-000178-20-BEErasmus Medical Centre40
进行中（未招募）
1 期
Therapy of MCT8 patients with the thyroid hormone analog Triac.This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.EUCTR2014-000178-20-ITErasmus Medical Centre40
已完成
2 期
Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial.Allan-Herndon-Dudley SyndromeMCT8 patient100146991004373910010335NL-OMON44458Erasmus MC, Universitair Medisch Centrum Rotterdam15
进行中（未招募）
1 期
Therapy of MCT8 patients with the thyroid hormone analog Triac.EUCTR2014-000178-20-FRErasmus Medical Centre40
进行中（未招募）
1 期
Therapy of MCT8 patients with the thyroid hormone analog Triac.This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.EUCTR2014-000178-20-DEErasmus Medical Centre40